Together with Mark Trusheim of MIT Sloan School of Management and Preston Atteberry, MD, the Drug Pricing Lab team articulated why biosimilars are not and will not effectively lower the price of biologic drugs after the period of market exclusivity.
Preston J. Atteberry, Peter B. Bach, Jennifer A. Ohn, Mark R. Trusheim
Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price. Drs. Bach and Mailankody argue that outcomes-based contracts are ill-suited to do so.